Eli Lilly sues compounders and medical spas over sales of unapproved copycats of its diabetes blockbuster Mounjaro
Eli Lilly on Tuesday sued 10 medical spas, wellness centers and compounding pharmacies in Florida, Georgia, Arizona, Minnesota, Utah and Texas for selling unapproved and compounded versions of its blockbuster type 2 diabetes drug Mounjaro (tirzepatide).
Lilly is asking the defendants, several of whom use an unauthorized Mounjaro trademark on their websites, to stop providing drugs in violation of consumer protection laws. The company notes heightened safety concerns, saying some of these companies promise their patients that the drugs offer the same safety profile and clinical benefits as Mounjaro when they’re actually compounded versions that don’t adhere to the same FDA regulations as fully approved products.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.